Multiple Myeloma Clinical Trials in Barcelona

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Lemzoparlimab
  • +4 more
  • Tucson, Arizona
  • +57 more
2022-04-06
Apr 6, 2022
T
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)Therapy. A Phase 3, Randomized, Placebo-Controlled.
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Fountain Valley, California
  • +277 more
2022-03-23
Mar 23, 2022
G
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
2022-03-21
Mar 21, 2022
J
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +24 more
2022-03-25
Mar 25, 2022
J
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Dara SC
  • Dara IV
  • Boston, Massachusetts
  • +145 more
2022-03-24
Mar 24, 2022
J
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Southington, Connecticut
  • +63 more
2022-03-24
Mar 24, 2022
J
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Active, not recruiting
  • Multiple Myeloma
  • Whittier, California
  • +113 more
2022-03-24
Mar 24, 2022
J
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +152 more
2022-03-24
Mar 24, 2022
J
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • California City, California
  • +164 more
2022-03-24
Mar 24, 2022
J
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +87 more
2022-03-24
Mar 24, 2022
J
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
Recruiting
  • Multiple Myeloma
  • Carfilzomib 20 mg/m^2
  • +4 more
  • Gilbert, Arizona
  • +113 more
2022-03-24
Mar 24, 2022
J
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +158 more
2022-03-24
Mar 24, 2022
J
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
Active, not recruiting
  • Multiple Myeloma
  • No intervention
  • Tucson, Arizona
  • +85 more
2022-03-24
Mar 24, 2022
J
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
2022-03-24
Mar 24, 2022
J
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +145 more
2022-03-24
Mar 24, 2022
G
To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Birmingham, Alabama
  • +31 more
2022-03-21
Mar 21, 2022
G
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Yuma, Arizona
  • +140 more
2022-03-18
Mar 18, 2022
G
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Yuma, Arizona
  • +35 more
2022-03-17
Mar 17, 2022
G
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • Pom/dex (Pomalidomide plus low dose Dexamethasone)
  • Tucson, Arizona
  • +163 more
2022-02-25
Feb 25, 2022
P
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
Recruiting
  • Multiple Myeloma
  • Non-eligible for Autologous Stem Cell Transplantation (ASCT)
  • Arganda Del Rey, Spain
  • +32 more
2022-03-08
Mar 8, 2022
A
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Tucson, Arizona
  • +181 more
2022-03-04
Mar 4, 2022
O
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM - 2022
Terminated
  • Multiple Myeloma
  • Melphalan flufenamide (Melflufen)
  • +3 more
  • Boston, Massachusetts
  • +15 more
2022-03-04
Mar 4, 2022
E
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Not yet recruiting
  • Multiple Myeloma
  • Lille, France
  • +41 more
2022-02-16
Feb 16, 2022
O
Study of Melphalan Flufenamide (Melflufen) in Combination With Daratumumab in Relapsed Refractory Multiple Myeloma - 2022
Terminated
  • Relapse Multiple Myeloma
  • Multiple Myeloma
  • Melphalan Flufenamide
  • +2 more
  • Plovdiv, Bulgaria
  • +25 more
2022-02-16
Feb 16, 2022
H
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM
Recruiting
  • Multiple Myeloma in Relapse
  • +3 more
  • Gilbert, Arizona
  • +16 more
2022-03-03
Mar 3, 2022